- In 2020, Vedanta Biosciences (US) received funding from the Biomedical Advanced Research and Development Authority (BARDA) of USD 7.4 million to advance the clinical development of VE303 for high-risk Clostridioides difficile infection (CDI)
Frequently Asked Questions
The market is segmented based on , By Products (Prebiotics, Creams, Probiotics, Drugs, Others), Application (Digestive Health, Immune Health, Oral Health, Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others) - Industry Trends and Forecast to 2032
.
The Global Microbiome Modulator Market size was valued at USD 3.16 USD Billion in 2024.
The Global Microbiome Modulator Market is projected to grow at a CAGR of 13.3% during the forecast period of 2025 to 2032.
The major players operating in the market include Sanofi, Procter & Gamble, Bayer, DSM, DuPont, Yakult Honsha, BioGaia, Probi, Chr. Hansen Holding, Ingredion, Immuron, Pharmavite, MICROBIOME THERAPEUTICS, Otsuka America Pharmaceutical, Quorum Innovations, Merck Sharp & Dohme, Symbiotix Biotherapies, Ritter Pharmaceuticals.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
